Xenon Pharmaceuticals Inc.
XENE
Updated: 24/09/2026, 03:55:58
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
No summaries found.
- Share price
- $36.56
- Market cap
- $3.53B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Ian C. Mortimer
- Employees
- 364
- IPO date
- 05/11/2014
- Beta
- 0.616
- Last dividend
- $0.00
- Day range
- $36.07 – $39.51
- 52-week range
- $35.97 – $72.66
- 1-day performance
- -6.47%
- 1-year performance
- 1.64%
- Current drawdown (1Y)
- -49.68%
- CIK
- 0001582313
- CUSIP
- 98420N105
- ISIN
- CA98420N1050
- Created
- 07/12/2025, 15:09:32
- Last update
- 24/09/2026, 03:55:58
Track Xenon Pharmaceuticals Inc. with an AI analyst
See which prediction-market events move XENE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 14/05/2026, 18:40:55
Xenon Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 06:07:32
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 05:41:17
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Seeking Alpha • STOCK • 22/04/2026, 18:51:19
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Zacks Investment Research • STOCK • 19/03/2026, 14:01:26
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
GlobeNewsWire • STOCK • 12/03/2026, 17:01:00
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
GlobeNewsWire • STOCK • 10/03/2026, 23:39:00
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Zacks Investment Research • STOCK • 10/03/2026, 13:30:39
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
24/7 Wall Street • STOCK • 09/03/2026, 20:00:00
Xenon Pharmaceuticals Announces Proposed Public Offering
GlobeNewsWire • STOCK • 09/03/2026, 17:01:00
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge
Benzinga • STOCK • 09/03/2026, 15:50:02
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Seeking Alpha • STOCK • 09/03/2026, 15:17:59